Table 1 Patient demographics
|  | ACS (n = 889) |
|---|---|
Age (years), mean ± SD | 70 ± 12 |
Male, n (%) | 655 (74) |
STEMI, n (%) | 558 (63) |
NSTE-ACS, n (%) | 331 (37) |
Time from symptom onset to arrival (h), median (IQR) | 3 (1, 10) |
PCI, n (%) | 795 (89) |
CABG, n (%) | 44 (5) |
Conservative therapy, n (%) | 56 (6) |
Use of BMS, n (%) | 226 (25) |
Use of the DES, n (%) | 519 (59) |
Peak CK (IU/L), median (IQR) | 1066 (229,2467) |
Hospital stay (days), median (IQR) | 13 (8, 19) |
BMI, (kg/m2), mean ± SD | 24 ± 4 |
LVEF (%), mean ± SD | 51 ± 11 |
Cre (mg/dl), median (IQR) | 0.81 (0.66, 1.01) |
LDL (mg/dl), mean ± SD | 98 ± 34 |
HDL (mg/dl), mean ± SD * | 46 ± 14 |
CRP (mg/dl), median (IQR) | 0.2 (0.07, 0.83) |
Medical history/comorbidities | |
 Current/Ex-smoker, n (%) | 532 (59) |
 History of PCI/CABG, n (%) | 119 (13) |
 Hypertension, n (%) | 617 (69) |
 Dyslipidemia, n (%) | 528 (59) |
 Diabetes mellitus, n (%) | 334 (38) |
 Atrial fibrillation, n (%) | 105 (12) |
Therapeutic agents | |
 ASA, n (%) | 841 (95) |
 Ticlopidine/Clopidogrel, n (%) | 631 (71) |
 Prasugrel, n (%) | 142 (16) |
 Other antiplatelet agents, n (%) | 12 (0.1) |
 ACEI/ARB, n (%) | 645 (72) |
 Beta-blocker, n (%) | 627 (70) |
 Statin, n (%) | 798 (90) |
 Diuretics, n (%) | 258 (29) |
 OHA/insulin, n (%) | 217 (24) |
 SGLT2 inhibitor, n (%) | 8 (1) |
 Warfarin, n (%) | 85 (10) |
 DOACs, n (%) | 35 (4) |